Peter Söderkvist

Platform Scientific Director, Linköping University

Key publications

Integrative genomics reveals somatic NF1 mutations in sporadic pheochromocytomas.
Welander J, Bäckdahl M, Larsson C, Hareni N, Sivlèr, Söderkvist P, Gimm O.
Hum Mol Genet., 21 (26) 5406-5416, 2012.

Genetic Alterations in Mitochondrial DNA Are Complementary to Nuclear DNA Mutations in Pheochromocytomas.
Tabebi M, Łysiak M, Dutta RK, Lomazzi S, Turkina MV, Brunaud L, Gimm O, Söderkvist P.
Cancers (Basel). 14(2):269, 2022

Deletions on chromosome Y influence survival of glioblastoma patients.
Łysiak M, Malmström M, C, Roodakker K R, Sandberg E, Dimberg, Mudaisi M, Bratthäll C, Strandeus M, Milos P, Hallbeck Smits A, Söderkvist P.
Cancers (Basel). 13(7):1619, 2021

Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial.
Małgorzata Łysiak 1, Jyotirmoy Das 2 3, Annika Malmström, Peter Söderkvist.
Front Genet. 13:934519, 2022

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus M, Stenmark-Askmalm M, Söderkvist P.
Oncotarget. 2015 Jun 30;6(18):16663-73.

Alteration of a novel protease causes a spectrum of phenotypes including angle-closure glaucoma and posterior microphthalmia.
K S Nair, M Hmani-Aifa, Zain A. A Kearney, S Ben Salem, D R Macalinao, M Cosma, W Bouassida, B Hakim, Z Benzina, I Soto, P Söderkvist, G Howell, R Smith, H Ayadi, SWM John.
Nature Genetics, 43(6):579-84, 2011.

My research interest is focused to the the underlying mechansims in carcinogenesis, identification of susceptibility genes for tumors in general and more recently for brain and endocrine (e.g pheochromocytoma) tumors. How genes and genetic variants contribute to cancer and can be used for targeted therapies represents a major activity. Our research is performed mainly on patient cohorts and novel susceptibility genes and genetic variants are investigated for functionality in cell culture models. A major aim is the development of biomarkers and diagnostic tools for individualized treatment and clinical use. The use of molecular genetic technologies has also expanded to other diseases and studies on genetic variation in inflammatory diseases and in an international collaboration on familial eye disorders to identify contributing susceptibility genes and genetic variants.

Group Members:

Malgorzata Lysiak, PhD
Åsa Schippert, BMA
Mouna Tababi, PhD
Hugo Rossitti, MD
Malgorzata Trybula, Pharm Sc
Annika Malmström, MD, PhD
Oliver Gimm, MD, PhD

Last updated: 2023-06-13

Content Responsible: Hampus Persson(